Bioversys AG
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patient… Read more
Bioversys AG (BIOV) - Net Assets
Latest net assets as of : CHF- CHF
Based on the latest financial reports, Bioversys AG (BIOV) has net assets worth CHF- CHF as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF-) and total liabilities (CHF-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bioversys AG - Net Assets Trend (None–None)
This chart illustrates how Bioversys AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioversys AG (None–None)
The table below shows the annual net assets of Bioversys AG from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Bioversys AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Bioversys AG Competitors by Market Cap
The table below lists competitors of Bioversys AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sentral REIT
KLSE:5123
|
$132.80 Million |
|
Hangzhou Hota M&E Holdings Co. Ltd. A
SHE:001225
|
$132.80 Million |
|
Grand Fortune Securities Co Ltd
TWO:6026
|
$132.94 Million |
|
7707
TWO:7707
|
$133.06 Million |
|
Smart Parking Ltd
AU:SPZ
|
$132.77 Million |
|
908 Devices Inc
NASDAQ:MASS
|
$132.76 Million |
|
Stellar V Capital Corp. Class A Ordinary Shares
NASDAQ:SVCC
|
$132.75 Million |
|
COMER INDS S.P.A.
F:X5Q
|
$132.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioversys AG's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Bioversys AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioversys AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Bioversys AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $554,918,213
- Average return on equity (ROE) among peers: -212.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioversys AG (BIOV) | CHF- | N/A | N/A | $132.79 Million |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $482.21K |
| Newron Pharmaceuticals SpA (NWRN) | $67.72 Million | -7.80% | 0.08x | $319.05 Million |
| Spexis AG (SPEX) | $2.29 Million | -857.53% | 6.33x | $4.21 Million |
| Xlife Sciences AG (XLS) | $235.23 Million | 6.08% | 1.08x | $72.54 Million |